Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00976508 · ClinicalTrials.gov registry record · Phase 1
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00976508 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 24 participants.
The verdict
NCT00976508, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a Phase 1 study investigating the safety and tolerability of Figitumumab plus Pegvisomant for treatment of advanced solid tumors.
Interventions
- DRUG pegvisomant
- DRUG figitumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-11 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00976508
The ClinicalTrials.gov registry entry for NCT00976508 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pegvisomant is the first listed.
NCT00976508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00976508 about?
NCT00976508 is a clinical study titled "Figitumumab Combined With Pegvisomant For Advanced Solid Tumors". This is a Phase 1 study investigating the safety and tolerability of Figitumumab plus Pegvisomant for treatment of advanced solid tumors.
What is the current status of trial NCT00976508?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-11. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00976508?
The interventions under investigation include: pegvisomant (DRUG), figitumumab (DRUG).
Who is sponsoring clinical trial NCT00976508?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.